# Athna Biotech

Source: https://onco.cc/companies/athna-biotech/  
OnCo record `athna-biotech` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Athna Biotech develops nanomedicines, tiny drug-carrying particles, including one for early bladder cancer and one activated by radiotherapy for lung cancer. Both are in laboratory development.

## Summary

Athna Biotech develops nanomedicine and drug delivery platforms and carries them through preclinical development. Its news page records NCI awards to develop a salt-based nanomedicine for non-muscle invasive bladder cancer. In fiscal year 2026 NCI awarded it USD 937,492 under STTR award 2R42CA262399-02 for the bladder cancer nanomedicine and USD 1,098,560 under STTR award 5R42CA257584-03 for a radiation-activatable nanoparticle for lung cancer.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: Athna Biotech, Inc.; ATHNA BIOTECH, INC.
- HQ: Athens, GA
- Type: biotech
- Website: https://athnabiotech.com/

## Notes

- No named product on the company website. Read on athnabiotech.com and NIH RePORTER on 4 November 2026.

## Sources

- Official website: https://athnabiotech.com/
- NIH RePORTER: STTR award 2R42CA262399-02: https://reporter.nih.gov/project-details/11314266
- NIH RePORTER: STTR award 5R42CA257584-03: https://reporter.nih.gov/project-details/11399125

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- fronts: [Radiation Therapy](https://onco.cc/fronts/radiation/)
- technologies: [Radiodynamic therapy and radiosensitising nanoparticles](https://onco.cc/technologies/radiodynamic-therapy/), [Sonodynamic therapy](https://onco.cc/technologies/sonodynamic-therapy/)

---
JSON: https://onco.cc/api/v1/entities/athna-biotech.json